[1]Expansion of circulating stem-like CD8+ T cells by adding CD122-directed IL-2 complexes to radiation and anti-PD1 therapies in mice [2]Author Correction: Expansion of circulating stem-like CD8+ T cells by adding CD122-directed IL-2 complexes to radiation and anti-PD1 therapies in mice [3]The CD39 positive hepatitis B virus surface protein (HBVs)-targeted CAR-T and personalized tumor-reactive CD8+ T cells exhibit potent anti-hepatocellular carcinoma (HCC) activity. [4]Metabolic reprogramming of terminally exhausted CD8+ T cells by IL-10 enhances anti-tumor immunity. [5]Redefining chimeric antigen receptor T-cell (CAR-T) regulation: China's responses to address secondary cancer risks of CAR-T therapy [6]Granzyme B+CD8+T cells with terminal differentiated effector signature determine multiple sclerosis progression [7]High HPK1+PD-1+TIM-3+CD8+ T cells infiltration predicts poor prognosis to immunotherapy in NSCLC patients [8]Eradication of Hepatocellular Carcinoma by NKG2D-Based CAR-T Cells. [9]TMEM115 as an Oncogenic and Immunological Biomarker in Hepatocellular Carcinoma [10]Distribution, phenotype, functional and clinical relevance of CD8+CD103+ tissue-resident memory T cells in human gastric cancer.